BLOG

Scynexis submits NDA for oral ibrexafungerp for vaginal yeast infection

Scynexis announced today that it has submitted a new drug application to the FDA for oral ibrexafungerp for the treatment of vulvovaginal candidiasis, the second most common cause of vaginitis.